Clinical trials: Immunocompromised Patients
Parainfluenza
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.
- Trial name
- DAS181-2-05 (NCT01644877)
- Testing
- DAS181 dry powder, formulation F02
- Where
- 45 sites in United States
- Volunteers
- 111 people
- Sponsor
- Ansun Biopharma, Inc.
Neutropenia
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered intravenously (IV) or orally to immunocompromised pediatric participants.
- Trial name
- NCT02452034
- Testing
- Posaconazole IV solution, Posaconazole powder for oral suspension
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients.
- Trial name
- NCT07690943
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- LucasBio
RSV Infection
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised…
- Trial name
- MUSIC (NCT04484935)
- Testing
- Nirsevimab
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Actinic Keratoses, Squamous Cell Carcinomas
Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients
The purpose of this trial is to investigate the prevention of actinic keratoses and squamous cell carcinomas by local application of MD-3511356 in comparison to standard sun protection measures in immunosuppressed solid organ…
- Trial name
- NCT01532453
- Testing
- MD-3511356, Standard Sun Protection Measures
- Where
- 10 sites in Austria, Czechia and 7 more
- Volunteers
- 244 people
- Sponsor
- Spirig Pharma Ltd.
Immunodeficiency and Suspected Infection
Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.
The study patients are patients suffering from primary or secondary immunodeficiencies investigated in the Hospital Necker for a suspected infectious disease.
- Trial name
- PATHOQUEST1 (NCT02007642)
- Testing
- Blood sampling / Body fluid sampling
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Pathoquest
Neutropenia
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count…
- Trial name
- NCT00056381
- Testing
- Anidulafungin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pfizer
Herpes Zoster, Herpes Zoster-related Complications
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
This study will evaluate the safety and immunogenicity of a heat-treated VZV vaccine in autologous or allogeneic hematopoietic cell transplant (HCT) recipients, human immunodeficiency virus (HIV)-infected participants with a…
- Trial name
- NCT00535236
- Testing
- V212
- Volunteers
- 341 people
- Sponsor
- Merck Sharp & Dohme LLC
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
- Trial name
- NCT00292071
- Testing
- caspofungin acetate
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Neoplasms, Neutropenia
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
The purpose of this observational study is to investigate whether a sufficient concentration of itraconazole can influence disappearance of a fever (defeverscence) when intravenous (into the vein) itraconazole is administered for…
- Conditions
- Hematologic Neoplasms, Neutropenia, Fever
- Trial name
- NCT01021683
- Testing
- Itraconazole
- Volunteers
- 203 people
- Sponsor
- Janssen Korea, Ltd., Korea
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma, Alpha Radiation
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Conditions
- Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
- Trial name
- DaRT (NCT06615635)
- Testing
- DaRT seeds
- Where
- 11 sites in United States, Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.
Candidiasis, Esophageal, HIV Infections
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.
- Trial name
- NCT00002132
- Testing
- Itraconazole, Fluconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen Pharmaceuticals
COVID-19, SARS-CoV-2
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
- Trial name
- VICTORIA (NCT05057897)
- Testing
- AZD1222
- Where
- 4 sites in Thailand, Ukraine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
SARS-CoV-2
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
- Trial name
- NCT05366322
- Where
- United States
- Volunteers
- 124,879 people
- Sponsor
- ModernaTX, Inc.
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups.
- Trial name
- MONET (NCT05842967)
- Testing
- RSVpreF
- Where
- 36 sites in United States
- Volunteers
- 885 people
- Sponsor
- Pfizer
COVID-19
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
- Trial name
- NCT05438602
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Chikungunya Virus Infection
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
This was a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.
- Trial name
- NCT06028841
- Testing
- VLA1553
- Sponsor
- Valneva Austria GmbH
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer